Leerink Partnrs Has Pessimistic Outlook of RVMD Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share estimate for Revolution Medicines to ($1.45), down from the prior estimate of ($1.07), reflecting a pessimistic outlook.
• The company reported a Q2 EPS of ($1.31), missing the consensus estimate of ($0.94), while revenue remained unchanged compared to the previous year.
• Despite the negative outlook, Revolution Medicines has a consensus rating of "Buy" from eleven analysts, with a consensus target price of $68.82.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($1.45) per share for the quarter, down from their prior estimate of ($1.07). The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.61) EPS, FY2025 earnings at ($5.50) EPS and FY2026 earnings at ($5.25) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.37). During the same quarter in the prior year, the business posted ($0.81) EPS. The company's quarterly revenue was up .0% compared to the same quarter last year.

Several other equities research analysts also recently commented on the stock. Wedbush restated an "outperform" rating and issued a $73.00 target price (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Guggenheim restated a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Oppenheimer boosted their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Finally, The Goldman Sachs Group assumed coverage on Revolution Medicines in a research note on Tuesday, July 15th. They issued a "buy" rating and a $65.00 target price for the company. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, Revolution Medicines has a consensus rating of "Buy" and a consensus target price of $68.82.

Revolution Medicines Stock Up 0.1%

Shares of NASDAQ:RVMD opened at $35.00 on Monday. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $62.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. The company's fifty day moving average is $38.42 and its 200-day moving average is $38.74. The company has a market capitalization of $6.54 billion, a PE ratio of -7.78 and a beta of 1.16.

Institutional Trading of Revolution Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Boxer Capital Management LLC bought a new position in Revolution Medicines in the fourth quarter valued at about $187,184,000. Janus Henderson Group PLC boosted its holdings in Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after acquiring an additional 3,346,755 shares during the last quarter. Lunate Capital Ltd bought a new position in Revolution Medicines in the first quarter valued at about $77,658,000. Farallon Capital Management LLC boosted its holdings in Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock valued at $579,498,000 after acquiring an additional 1,931,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Revolution Medicines in the first quarter valued at about $59,173,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.